Clinician Resources

• IHS National Pharmacy and Therapeutics Committee:
  • Mpox Emerging Treatments Updates

• Centers for Disease Control and Prevention:
  • Clinical Considerations for Mpox in Children and Adolescents Exit Disclaimer: You Are Leaving www.ihs.gov 
  • Information for Healthcare Professionals Exit Disclaimer: You Are Leaving www.ihs.gov 
  • JYNNEOS Vaccine Exit Disclaimer: You Are Leaving www.ihs.gov 
  • Tecovirimat (TPOXX) Treatment Exit Disclaimer: You Are Leaving www.ihs.gov 
  • Clinicians - Frequently Asked Questions Exit Disclaimer: You Are Leaving www.ihs.gov 
  • JYNNEOS Vaccine Standing Orders
    • Subcutaneous (0.5ml dose) Exit Disclaimer: You Are Leaving www.ihs.gov  [PDF]
    • Intradermal (0.1ml dose) >/=18yo Exit Disclaimer: You Are Leaving www.ihs.gov  [PDF]
  • Morbidity and Mortality Weekly Report Strategies Adopted by Gay, Bisexual, and Other Men Who Have Sex with Men to Prevent Mpox virus Transmission Exit Disclaimer: You Are Leaving www.ihs.gov   

• Jynneos Vaccine EXAMPLE Competency Exam [PDF - 173 KB]
  • IHS Area Vaccine Points of Contact [PDF] have the EXAMPLE Competency Exam Answer Key to share
• Intradermal Injection Guidance [PDF - 151 KB]
  • EXAMPLE Intradermal Injection Competency Assessment [PDF - 226 KB]
• Documents and Forms
  • Jynneos Vaccination PATIENT Record for EHR [PDF - 575 KB]
  • Jynneos Vaccination EMPLOYEE Record for Employee Medical File [PDF - 565 KB]
  • Mpox Vaccine Redistribution Worksheet [PDF - 288 KB]

Access to mpox countermeasures within the IHS:

• The IHS National Service Supply Center has received a limited supply of Jynneos vaccine and the FDA investigational new drug, tecovirimat (TPOXX), for mpox treatment in certain individuals. NSSC began distributing mpox countermeasures in mid-August based on need and equity. IHS operated facilities, tribal health programs and urban Indian organizations should work with their Area Vaccine and Therapeutics points of contact and the NSSC to place orders.